AHA blog: PhRMA-led coalition seeks to dismantle 340B at patients’ expense
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug Pricing Program so that they can continue to pad their billion-dollar bottom lines,” writes Bharath Krishnamurthy, director of health analytics and policy for the AHA. “The self-serving policy proposals outlined by this new alliance directly contravene Congress’ oft-demonstrated intent to preserve the 340B program over the last 30 years. Those most impacted by this coalition’s assault on 340B are the millions of patients who will lose access to lifesaving medicines and to other vital health care services supported by the program.” READ MORE
Related News Articles
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Blog
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…